2026 Global: Drug Delivery Devices Market-Competitive Review (2032) report
Description
The 2026 Global: Drug Delivery Devices Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Several leading firms shape the Drug Delivery Devices Market through integrated device platforms, clinical pipelines, and manufacturing scale. Novo Nordisk, headquartered in Bagsværd, Denmark, maintains a global leadership position in injectable delivery systems, encompassing prefilled syringes, device linked pens, and autoinjectors for diabetes management. The company's sustained emphasis on subcutaneous delivery supports high-volume manufacturing, regulatory flexibility, and patient convenience, reinforcing its role in biologic and insulin therapy. Medtronic, based in Dublin, Ireland, complements this landscape with infusion pumps, external insulin delivery interfaces, and connected devices that integrate therapeutic administration with digital health functionality. Terumo, headquartered in Tokyo, Japan, contributes breadth across syringes, insulin pens, infusion sets, and needle technologies, leveraging scale in hospital and homecare settings. B. Braun Melsungen, located in Melsungen, Germany, extends the portfolio with infusion therapy components, safety syringes, and delivery devices engineered for critical care and dialysis pathways. These developments signify convergence of medicine and technology.
West Pharmaceutical Services, based in Exton, United States, ranks prominently in the drug delivery ecosystem through its packaging components, prefillable syringes, and customized polymer solutions that enable accurate dose delivery. The firm's integrated approach to containment and device compatibility supports precision medicine programs spanning biologics and small molecules. Becton, Dickinson and Company, headquartered in Franklin Lakes, United States, remains a foundational supplier of syringes, needle safety devices, and automation solutions employed in hospital and community settings, with recent emphasis on patient safety and compliant manufacturing processes. Gerresheimer, AG, with its headquarters in Düsseldorf, Germany, contributes a broad portfolio of glass and plastic primary packaging for injectables, coupled with prefilled syringes and metal, polymer, and glass delivery components that integrate with autoinjector platforms. Through these players, the market benefits from standardized interfaces, scalable production, and rigorous quality control, enabling faster regulatory approvals and patient access across diabetes, oncology, and autoimmune therapies.
Insulet Corporation, headquartered in Acton, United States, specializes in wearable insulin pump systems that enable autonomous dose customization and improved patient adherence. The company emphasizes integrated devices, cloud connectivity, and remote monitoring to support drip-free subcutaneous delivery and data-driven therapy adjustments. Ypsomed Group, based in Burgdorf, Switzerland, concentrates on pen-based delivery platforms, syringe devices, and autoinjector solutions that address patient preferences and dose accuracy across autoimmune and metabolic disorders. Its modular pen ecosystem supports scalable adoption, while partnerships with pharmaceutical manufacturers expand access to self administered therapies. Nipro Corporation, headquartered in Osaka, Japan, supplies sterile components including glass and polymer syringes, vials, and related infusion materials that underpin reliable drug delivery across hospital and home settings. Collectively, these firms illustrate the diversification of device modalities within the Drug Delivery Devices Market, highlighting consumer convenience, safety enhancements, and interoperable standards that accelerate patient access to biologics and small molecule therapies globally.
Several leading firms shape the Drug Delivery Devices Market through integrated device platforms, clinical pipelines, and manufacturing scale. Novo Nordisk, headquartered in Bagsværd, Denmark, maintains a global leadership position in injectable delivery systems, encompassing prefilled syringes, device linked pens, and autoinjectors for diabetes management. The company's sustained emphasis on subcutaneous delivery supports high-volume manufacturing, regulatory flexibility, and patient convenience, reinforcing its role in biologic and insulin therapy. Medtronic, based in Dublin, Ireland, complements this landscape with infusion pumps, external insulin delivery interfaces, and connected devices that integrate therapeutic administration with digital health functionality. Terumo, headquartered in Tokyo, Japan, contributes breadth across syringes, insulin pens, infusion sets, and needle technologies, leveraging scale in hospital and homecare settings. B. Braun Melsungen, located in Melsungen, Germany, extends the portfolio with infusion therapy components, safety syringes, and delivery devices engineered for critical care and dialysis pathways. These developments signify convergence of medicine and technology.
West Pharmaceutical Services, based in Exton, United States, ranks prominently in the drug delivery ecosystem through its packaging components, prefillable syringes, and customized polymer solutions that enable accurate dose delivery. The firm's integrated approach to containment and device compatibility supports precision medicine programs spanning biologics and small molecules. Becton, Dickinson and Company, headquartered in Franklin Lakes, United States, remains a foundational supplier of syringes, needle safety devices, and automation solutions employed in hospital and community settings, with recent emphasis on patient safety and compliant manufacturing processes. Gerresheimer, AG, with its headquarters in Düsseldorf, Germany, contributes a broad portfolio of glass and plastic primary packaging for injectables, coupled with prefilled syringes and metal, polymer, and glass delivery components that integrate with autoinjector platforms. Through these players, the market benefits from standardized interfaces, scalable production, and rigorous quality control, enabling faster regulatory approvals and patient access across diabetes, oncology, and autoimmune therapies.
Insulet Corporation, headquartered in Acton, United States, specializes in wearable insulin pump systems that enable autonomous dose customization and improved patient adherence. The company emphasizes integrated devices, cloud connectivity, and remote monitoring to support drip-free subcutaneous delivery and data-driven therapy adjustments. Ypsomed Group, based in Burgdorf, Switzerland, concentrates on pen-based delivery platforms, syringe devices, and autoinjector solutions that address patient preferences and dose accuracy across autoimmune and metabolic disorders. Its modular pen ecosystem supports scalable adoption, while partnerships with pharmaceutical manufacturers expand access to self administered therapies. Nipro Corporation, headquartered in Osaka, Japan, supplies sterile components including glass and polymer syringes, vials, and related infusion materials that underpin reliable drug delivery across hospital and home settings. Collectively, these firms illustrate the diversification of device modalities within the Drug Delivery Devices Market, highlighting consumer convenience, safety enhancements, and interoperable standards that accelerate patient access to biologics and small molecule therapies globally.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
